← Back to Search

Mushroom-based Product

Mushroom-based Product for COVID-19 (MACH19 Trial)

Phase 1 & 2
Waitlist Available
Led By Andrew Shubov, MD
Research Sponsored by Gordon Saxe
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

MACH19 Trial Summary

This trial will compare two types of mushrooms to see if they help treat mild-to-moderate symptoms of COVID-19 in people who are self-quarantining at home. A total of 66 people will be in the study.

Who is the study for?
Adults over 18 with a recent COVID-19 diagnosis can join this trial. They must be able to track and report their health daily, not consume alcohol, cannabis, or dairy during the study, and use contraception if they're women of childbearing potential. People with severe symptoms needing hospitalization or those with liver disease, uncontrolled high blood pressure, kidney disease, pregnant or breastfeeding are excluded.Check my eligibility
What is being tested?
The trial is testing FoTv—a combination of two mushrooms—against a placebo in people managing mild-to-moderate COVID-19 at home. It's randomized (participants are put into groups by chance) and double-blind (neither participants nor researchers know who gets what treatment), involving 66 individuals to assess safety and feasibility.See study design
What are the potential side effects?
Since this is a study for safety and feasibility, specific side effects of FoTv aren't listed but could include typical reactions to supplements such as digestive discomfort or allergic reactions.

MACH19 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Alanine transaminase
Aspartate transaminase
+3 more
Secondary outcome measures
C-Reactive Protein
D-Dimer
Mental disorders
+10 more

MACH19 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MushroomsExperimental Treatment1 Intervention
Fomitopsis officinalis and Trametes versicolor
Group II: PlaceboPlacebo Group1 Intervention
Organic brown rice

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Gordon SaxeLead Sponsor
University of California, Los AngelesOTHER
1,538 Previous Clinical Trials
10,266,977 Total Patients Enrolled
21 Trials studying COVID-19
873,021 Patients Enrolled for COVID-19
University of California, IrvineOTHER
546 Previous Clinical Trials
1,923,147 Total Patients Enrolled
6 Trials studying COVID-19
2,010 Patients Enrolled for COVID-19

Media Library

FoTv (Mushroom-based Product) Clinical Trial Eligibility Overview. Trial Name: NCT04667247 — Phase 1 & 2
COVID-19 Clinical Trial 2023: FoTv Highlights & Side Effects. Trial Name: NCT04667247 — Phase 1 & 2
FoTv (Mushroom-based Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04667247 — Phase 1 & 2
COVID-19 Research Study Groups: Mushrooms, Placebo
~12 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top